Unknown

Dataset Information

0

Nanoparticles Presenting Potent TLR7/8 Agonists Enhance Anti-PD-L1 Immunotherapy in Cancer Treatment.


ABSTRACT: Cancer immunotherapy can be augmented with toll-like receptor agonist (TLRa) adjuvants, which interact with immune cells to elicit potent immune activation. Despite their potential, use of many TLRa compounds has been limited clinically due to their extreme potency and lack of pharmacokinetic control, causing systemic toxicity from unregulated systemic cytokine release. Herein, we overcome these shortcomings by generating poly(ethylene glycol)-poly(lactic acid) (PEG-PLA) nanoparticles (NPs) presenting potent TLR7/8a moieties on their surface. The NP platform allows precise control of TLR7/8a valency and resulting surface presentation through self-assembly using nanoprecipitation. We hypothesize that the pharmacokinetic profile of the NPs minimizes systemic toxicity, localizing TLR7/8a presentation to the tumor bed and tumor-draining lymph nodes. In conjunction with antiprogrammed death-ligand 1 (anti-PD-L1) checkpoint blockade, peritumoral injection of TLR7/8a NPs slows tumor growth, extends survival, and decreases systemic toxicity in comparison to the free TLR7/8a in a murine colon adenocarcinoma model. These NPs constitute a modular platform for controlling pharmacokinetics of immunostimulatory molecules, resulting in increased potency and decreased toxicity.

SUBMITTER: Smith AAA 

PROVIDER: S-EPMC7497526 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Nanoparticles Presenting Potent TLR7/8 Agonists Enhance Anti-PD-L1 Immunotherapy in Cancer Treatment.

Smith Anton A A AAA   Gale Emily C EC   Roth Gillie A GA   Maikawa Caitlin L CL   Correa Santiago S   Yu Anthony C AC   Appel Eric A EA  

Biomacromolecules 20200820 9


Cancer immunotherapy can be augmented with toll-like receptor agonist (TLRa) adjuvants, which interact with immune cells to elicit potent immune activation. Despite their potential, use of many TLRa compounds has been limited clinically due to their extreme potency and lack of pharmacokinetic control, causing systemic toxicity from unregulated systemic cytokine release. Herein, we overcome these shortcomings by generating poly(ethylene glycol)-poly(lactic acid) (PEG-PLA) nanoparticles (NPs) pres  ...[more]

Similar Datasets

| S-EPMC7228744 | biostudies-literature
| S-EPMC8564903 | biostudies-literature
| S-EPMC10548684 | biostudies-literature
| S-EPMC7455180 | biostudies-literature
| S-EPMC9714418 | biostudies-literature
| S-EPMC9113929 | biostudies-literature
| S-EPMC6192054 | biostudies-literature
| S-EPMC6805442 | biostudies-literature
| S-EPMC6237477 | biostudies-literature
| S-EPMC6937231 | biostudies-literature